Preliminary Programme

19th Annual ENETS Conference

Hybrid Event, 10 - 11 March 2022, in Barcelona, Spain

Annual ENETS Conference in 2022

The scientific faculty has prepared a first-class scientific programme that will allow you to follow the latest science and research in the field of neuroendocrine tumor disease. Please look at the preliminary programme.

Become an ENETS member today and benefit from the best conference fee.

For our 19th Annual ENETS Conference and the 1st World NET Forum in 2022, ENETS will offer up to 20 travel grants for physicians and scientists with a particular interest in neuroendocrine neoplasms. Travel grants will be awarded to scientists who have submitted outstanding abstracts in basic, translational, and clinical science.

Preliminary Programme

10 - 11 March 2022 - Hybrid Event

Welcome

Time: Thursday 08:30 - 08:40

Opening session: Are we ready for precision medicine in NEN in 2022?

Time: Thursday 08:40 - 09:00

Session 1: Molecular pathology and precision medicine

Time: Thursday 09:00 - 10:30
09:00 - 09:05 Introduction
09:05 - 09:20 Theranostic markers in well differentiated NET with case presentation
09:20 - 09:35 Theranostic markers in NEC with case presentation
09:35 - 09:55 Panel discussion
09:55 - 10:05 Best abstract
10:05 - 10:15 Best abstract
10:15 - 10:30 Putting molecular profiling into perspective

Coffee break

Time: Thursday 10:30 - 11:00

Session 2: New developments in nuclear medicine

Time: Thursday 11:00 - 12:30
11:00 - 11:15 Moving beyond RECIST-PFS for assessment of outcome after PRRT
11:15 - 11:20 Discussion
11:20 - 11:35 Integration of functional imaging and molecular pathology for optimal treatment selection in NEN
11:35 - 11:40 Discussion
11:40 - 11:55 Modulation of targets for increasing the efficacy of PRRT
11:55 - 12:00 Discussion
12:00 - 12:08 Best abstract
12:08 - 12:13 Discussion
12:13 - 12:20 Best abstract
12:20 - 12:30 Discussion

Nurse symposium

Time: Thursday 11:00 - 12:30

Lunch break

Time: Thursday 12:30 - 14:00

Satellite symposium – Industry-sponsored

Time: Thursday 12:30 - 14:00

Session 3A: Defining success and individualising therapy in NEN

Time: Thursday 14:00 - 15:15
14:00 - 14:10 What is the most appropriate outcome for quality-of-life measurements in trials and daily practice?
14:10 - 14:20 Individualised treatment strategies
14:20 - 14:30 Long term sequelae versus toxicity
14:30 - 14:40 Patient engagement in treatment decisions
14:40 - 14:50 Patient voice/story
14:50 - 15:15 Discussion

Session 3B: Best abstracts – Preclinical science

Time: Thursday 14:00 - 15:15

Coffee break

Time: Thursday 15:15 - 15:40

Session 4A: Joint session: European Society of Surgical Oncology (ESSO) / ENETS

Time: Thursday 15:40 - 17:05
PART 1 (15:40 - 16:20)
15:40 - 15:55 A message from the ESSO president: Surgical oncology and NEN disease – Does one size fit all?
15:55 - 16:00 Discussion
16:00 - 16:15 Trust the surgeon – Individual approaches and outcomes of pancreatic surgery
16:15 - 16:20 Discussion
PART 2: Surgery with curative intent to liver dominant disease – What is the number one choice? (16:20 - 17:05)
16:20 - 16:30 The surgeon: Resection is king / Direct visibility / Regenerative potential and safe techniques
16:30 - 16:40 The interventional radiologist: (Stereotactic) ablation does better than any surgical approach
16:40 - 16:50 The transplant surgeon: Extended donor criteria will push transplantation to treatment of choice
16:50 - 17:05 Discussion

Session 4B: Best abstracts – Clinical science

Time: Thursday 15:40 - 16:45

ENETS General Assembly (Members only)

Time: Thursday 17:15 - 18:15

Satellite symposium – Industry-sponsored

Time: Thursday 18:30 - 20:00

Satellite symposium – Industry-sponsored

Time: Friday 07:30 - 08:30

Session 5A: Systemic treatment of advanced NETs – Have we made any progress?

Time: Friday 08:30 - 10:10
08:30 - 08:50 What’s changing our practice?
08:50 - 08:55 Discussion
Debate on the optimal sequencing of systemic therapy in advanced Pancreatic NETs – What’s the preferred option upon progression after one year of SSA therapy? (08:55 - 10:10)
08:55 - 09:05 Clinical case presentation
09:05 - 09:10 Discussion
09:10 - 09:18 Defending everolimus
09:18 - 09:26 Defending PRRT
09:26 - 09:34 Defending angiogenesis inhibitors
09:34 - 09:42 Defending chemotherapy
09:42 - 09:50 Defending high dose SSA
09:50 - 10:10 Panel discussion

Session 5B: Best abstracts – Preclinical and clinical science

Time: Friday 08:30 - 10:10

Coffee break

Time: Friday 10:10 - 10:40

Session 6: New developments in the management of high-grade NEC

Time: Friday 10:40 - 12:00
10:40 - 10:55 Impact of primary tumor site on treatment choices
10:55 - 11:00 Discussion
11:00 - 11:15 Do recent results from clinical trials change the clinical management?
11:15 - 11:20 Discussion
11:20 - 11:35 Current clinical trial landscape in NEC and future perspectives
11:35 - 11:40 Discussion
11:40 - 11:50 Best abstract
11:50 - 12:00 Best abstract

ENETS / INCA symposium

Time: Friday 10:40 - 12:00

Lunch break

Time: Friday 12:00 - 13:30

Satellite Symposium – Industry-sponsored

Time: Friday 12:00 - 13:30

Session 7: Pheochromocytoma, paraganglioma and medullary thyroid carcinoma

Time: Friday 13:30 - 14:30
13:30 - 13:45 Biomarkers and functional imaging of pheochromocytoma / paraganglioma and medullary thyroid cancer – Which modality should be used?
13:45 - 13:50 Discussion
13:50 - 14:05 Personalized treatment in advanced medullary thyroid carcinoma
14:05 - 14:10 Discussion
14:10 - 14:25 Personalized treatment in advanced paragangliomas and pheochromocytomas
14:25 - 14:30 Discussion

Life Achievement Award

Time: Friday 14:30 - 14:50
14:30 - 14:35 Laudatio
14:35 - 14:50 Recipient and keynote address

Awards ceremony

Time: Friday 14:50 - 15:15

Session 8: What’s new in 2021/2022?

Time: Friday 15:15 - 16:00
15:15 - 15:45 Best abstract resumé - Clinical science
15:45 - 16:00 Review of basic science

Welcome the new ENETS Chair & Closing comments

Time: Friday 16:00 - 16:15